【作者】 刘杰；

【导师】 冯烈；

【作者基本信息】 暨南大学 ， 内科学， 2011， 硕士

【摘要】 目的：本课题拟观察复方血栓通胶囊对糖尿病肾病患者尿微量白蛋白、半胱氨酸蛋白酶抑制剂C等实验室指标的影响,并观察其安全性,为探索一种新的能有效治疗糖尿病肾病的中医药提供可靠科学依据及临床参考数据。方法：本课题76例患者均来自暨南大学附属第一医院内分泌科,按尿白蛋白/肌酐水平分为正常白蛋白尿组(NAU)、低值白蛋白尿(LAU)、高值白蛋白尿组(HAU)、极高值白蛋白尿组(VHAU)四组,采用自身对照方法进行研究。患者进行12周基础治疗后,加服复方血栓通胶囊：口服,3粒/次,3次/日。分别于治疗前及治疗12周后对尿微量白蛋白、血脂、尿酸及肝肾功能指标进行评估,评价其治疗前后差异性。采用SPSS 16.0统计软件包对数据进行统计分析。结果：1.HAU组治疗后尿微量白蛋白较前明显下降,差异有统计学意义(P<0.001), LAU组治疗后尿微量白蛋白较前明显下降,差异有统计学意义(P<0.05), NAU组及VHAU组治疗前后差异无统计学意义(P>0.05)。2.将所有患者按治疗前的Cys-C水平分为正常组及异常组,分析发现正常组的患者治疗前后Cys-C水平未出现明显变化,异常组的患者Cys-C水平在治疗后较前明显下降,差异有统计学意义(P<0.05)。3.治疗前血脂、尿酸及肝肾功能正常的患者在治疗前后上述指标的差异无统计学意义(P>0.05)。4.治疗前血脂、尿酸及肝肾功能异常的患者在治疗后实验室指标均有所改善,差异有统计学意义(P<0.05)。结论：复方血栓通胶囊临床观察,结果显示：该中成药可以明显降低早中期糖尿病肾病患者的尿微量白蛋白,并可以降低患者已经升高的半胱氨酸蛋白酶抑制剂水平,对肝肾功能正常的患者无明显影响,对指标异常的患者有护肝护肾及降血脂的作用。提示复方血栓通胶囊治疗早中期糖尿病肾病有较好的效果,为进一步推广应用提供了理论依据。更多还原

【Abstract】 Objective:The subject intended to observe the influence of Fufang Xueshuantong capsule on urinary albumin, cystatin C and other laboratory indices in patients with diabetic nephropathy and the efficacy and safety of it. In order to provide a scientific basis for a new treatment of diabetic nephropathy in Chinese medicine.Methods:60 patients from the first affiliated hospital of Jinan university, Department of Endocrinology were divided into normal albuminuria group (NAU), low-grade albuminuria group(LAU), high-grade albuminuria group(HAU) and very high-grade albuminuria group (VHAU) according to the level of ACR. Fufang Xueshuantong capsule were plus to all patients: oral,3 tablets/time,3 times/day after basic treatment of 12 weeks. The course of treatment lasted for 12 weeks, during that time the changes of lab indices which included urinary albumin, blood lipids, uric acid, liver and kidney function indicators were monitored and recorded. The differences between the symptom index before and after treatment were then calculated and tested using SPSS 16.0.Results:1. After treatment, urinary albumin was significantly decreased in HAU group(P<0.001) and LAU group (P＜0.05) with statistically significant. While there’s no statistical significant difference in NAU group and VHAU group (P> 0.05).2. Patients were divided into normal group and abnormal group by Cys-C level before treatment. There was no marked change of the Cys-C level in normal group patients, while after treatment, the Cys-C level of abnormal group patients decreased obviously with statistical significance (P＜0.05).3. There was no statistical significant difference before and after treatment in blood lipids, uric acid, liver and renal functions in patients who had normal lab indices stated above before treatment (P>0.05).4. Blood lipids, uric acid, liver and renal functions patients were significantly improved with statistical significant difference after treatment in patients with abnormal lab indices stated above before treatment (P< 0.05).Conclusion:Fufang Xueshuantong capsule can decrease urinary albumin, and the elevated Cys-C level, with good effect and safety. It had no significant effect on the index of patients with normal liver and kidney function while it had protection effect and lipid-lowering to the patients with abnormal liver and kidney fonctions. The present study demonstrated that Fufang Xueshuantong capsule may be used to treat DN.更多还原